Fundamentals Overview
Horizon Therapeutics Public Limited Company is in the middle of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
+0% upside vs price
Profitability
Risk (Beta)
1.01 — in line vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Pressures (Sell):
Sentiment weakening (12 downgrades)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Recent institutional grades: majority downgrades. Current institutional positions: Buy: 5, Equal Weight: 2, Hold: 2, Market Perform: 4, Neutral: 5, Outperform: 6, Overweight: 6.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $116.30; current price is $116.30. That’s a +0% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 62.12 |
| DCF value (model) | $116.30 (0% vs price) |
| PEG (TTM) | N/A |
| P/B (TTM) | 5.25 |
| P/S (TTM) | 7.33 |
| P/FCF (TTM) | 23.51 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.85 |
| Quick Ratio (TTM) | 3.67 |
| Cash Ratio (TTM) | 2.48 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 14.37% |
| Gross margin (TTM) | 74.64% |
| Operating margin (TTM) | 17.01% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for HZNP.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Wells Fargo | downgrade | Overweight | Equal Weight | 2022-12-13 |
| BMO Capital | downgrade | Outperform | Market Perform | 2022-12-13 |
| Guggenheim | downgrade | Buy | Neutral | 2022-12-13 |
| SVB Leerink | downgrade | Outperform | Market Perform | 2022-12-13 |
| BMO Capital | downgrade | Outperform | Market Perform | 2022-12-12 |
| Stifel | downgrade | Buy | Hold | 2022-12-12 |
| SVB Leerink | downgrade | Outperform | Market Perform | 2022-12-12 |
| Wells Fargo | downgrade | Overweight | Equal Weight | 2022-12-12 |
| Guggenheim | downgrade | Buy | Neutral | 2022-12-12 |
| Stifel | downgrade | Buy | Hold | 2022-12-11 |
| Piper Sandler | maintain | Overweight | Overweight | 2022-12-07 |
| Piper Sandler | maintain | Overweight | Overweight | 2022-12-06 |
| SVB Leerink | maintain | Outperform | Outperform | 2022-11-03 |
| SVB Leerink | maintain | Outperform | Outperform | 2022-11-02 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2022-11-01 |
| Piper Sandler | maintain | Overweight | Overweight | 2022-10-25 |
| Piper Sandler | maintain | Overweight | Overweight | 2022-10-24 |
| BMO Capital | maintain | Outperform | Outperform | 2022-08-04 |
| SVB Leerink | upgrade | Market Perform | Outperform | 2022-08-04 |
| Goldman Sachs | maintain | Buy | Buy | 2022-08-04 |
| Morgan Stanley | maintain | Overweight | Overweight | 2022-08-04 |
| UBS | downgrade | Buy | Neutral | 2022-08-04 |
| Goldman Sachs | maintain | Buy | Buy | 2022-08-03 |
| BMO Capital | maintain | Outperform | Outperform | 2022-08-03 |
| SVB Leerink | upgrade | Market Perform | Outperform | 2022-08-03 |
| UBS | downgrade | Buy | Neutral | 2022-08-03 |
| Morgan Stanley | maintain | Overweight | Overweight | 2022-08-03 |
| UBS | maintain | Buy | Buy | 2022-07-05 |
| UBS | maintain | Buy | Buy | 2022-07-04 |
| UBS | maintain | Buy | Buy | 2022-06-14 |